F
Federico Giulietti
Researcher at European Society of Hypertension
Publications - 47
Citations - 533
Federico Giulietti is an academic researcher from European Society of Hypertension. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 11, co-authored 37 publications receiving 342 citations. Previous affiliations of Federico Giulietti include Marche Polytechnic University.
Papers
More filters
Journal ArticleDOI
Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
TL;DR: In this paper, a review of the evidence of RAS arm disequilibrium in COVID-19 and the hypothesis of a beneficial role of renin-angiotensin modulation supported by preclinical and clinical studies is presented.
Journal ArticleDOI
Cardiac Natriuretic Peptides, Hypertension and Cardiovascular Risk.
Riccardo Sarzani,Francesco Spannella,Federico Giulietti,Paolo Balietti,Guido Cocci,Marica Bordicchia +5 more
TL;DR: Cardiac NPs system, with its two receptors and a neutralizing enzyme, might represent one of the main targets to treat these multiple related conditions and to reduce hypertension and metabolic-related CV risk.
Journal ArticleDOI
Renal effects of Sacubitril/Valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study
Francesco Spannella,Marco Marini,Federico Giulietti,Giulia Rosettani,Matteo Francioni,Gian Piero Perna,Riccardo Sarzani +6 more
TL;DR: Renal function improved after 12 months compared to historical controls and a greater benefit was found in subjects aged aged aged < 65 years (p for interaction = 0.001), which represents an important confirmation outside the peculiar world of RCTs.
Journal ArticleDOI
Effect of sacubitril/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials
TL;DR: The role of sacubitril/valsartan on preservation of renal function, especially in older patients and HF patients with preserved ejection fraction is supported, however, evidence is currently limited to HF patients, while the renal outcome of sacubsubitrill/valsArtan therapy outside the HF setting needs to be further investigated.
Journal ArticleDOI
Prevalence and Control of Dyslipidemia in Patients Referred for High Blood Pressure: The Disregarded “Double-Trouble” Lipid Profile in Overweight/Obese
TL;DR: Dyslipidemia is still too often neglected in hypertensives, especially in patients at higher CV risk, and overweight/obese patients have a “double-trouble” atherogenic lipid pattern likely driven by adiposity.